Bayer 2022: Delivering Value Creation

Roadshow
Singapore & Australia
January 15th - 17th, 2019

Werner Baumann
CEO Bayer AG
Disclaimer

Cautionary Statements Regarding Forward-Looking Information

This presentation contains forward-looking statements. A forward-looking statement is any statement that does not relate to historical facts and events, but rather reflects Bayer’s current beliefs, expectations and assumptions regarding the future. This applies, in particular, to statements in this presentation on revenue growth, including product introductions and peak sales potential, synergies, especially in relation to the acquisition and integration of Monsanto Company, portfolio adjustments, cost reduction, financial targets and earnings, cash flow generation, deleveraging and other similar statements relating to future performance, including with respect to the markets in which Bayer is active.

Although the forward-looking statements contained in this presentation are based upon what Bayer’s management believes are reasonable assumptions, they necessarily involve known and unknown risks and uncertainties that could cause actual results and future events to differ materially from those anticipated in such statements. Forward-looking statements are not guarantees of future performance and undue reliance should not be placed on them. Bayer undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.

For more information on factors that could cause actual results and future events to differ from those anticipated in forward looking statements, please refer to the factors discussed in Bayer’s public reports which are available on the Bayer website at https://www.investor.bayer.com/en/reports/annual-reports/overview/, including in the Annual Report 2017 under the caption “Report on Future Perspectives and on Opportunities and Risks”.

### 2018: Progress Across all Divisions

Delivering on Guidance Despite Headwinds

<table>
<thead>
<tr>
<th>Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>// 2018 on track</td>
</tr>
<tr>
<td>// Status of Glyphosate litigation</td>
</tr>
<tr>
<td>// Value crystallization of Covestro stake</td>
</tr>
<tr>
<td>// Net financial debt at ~€36bn by end of 2018, ~€3bn ahead of plan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Crop Science</th>
</tr>
</thead>
<tbody>
<tr>
<td>// Growth ahead of competition and best-in-class profitability¹</td>
</tr>
<tr>
<td>// Full recovery in Brazil</td>
</tr>
<tr>
<td>// Successful start of integration</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pharmaceuticals</th>
</tr>
</thead>
<tbody>
<tr>
<td>// Growth at rate of competition²</td>
</tr>
<tr>
<td>// cGMP remediation in Leverkusen fully on track</td>
</tr>
<tr>
<td>// Xarelto approvals/launch in CAD/PAD in EU/US</td>
</tr>
<tr>
<td>// Progress with Larotrectinib and Darolutamide</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Consumer Health</th>
</tr>
</thead>
<tbody>
<tr>
<td>// Growth acceleration plan with strengthened management underway</td>
</tr>
<tr>
<td>// Return to growth in H2 2018</td>
</tr>
<tr>
<td>// Portfolio further focused through divestiture of Rx dermatology</td>
</tr>
</tbody>
</table>

¹ Reported data peer group; ² IQVIA; cGMP: current Good Manufacturing Practices; CAD: Coronary Artery Disease, PAD: Peripheral Artery Disease
We Will Create Significant Value Through 2022 and Beyond
Focus on Execution and Driving Sustained Profitable Growth…

1. We have completed Bayer’s portfolio transformation into a global leader in Health & Nutrition

2. The next phase is focused on driving value creation through (i) growth ahead of competition enabled by innovation and portfolio measures (ii) profitability enhancement through Bayer 2022 synergy and efficiency programs and (iii) strong cash generation

3. We target Sales, Core EPS and FCF CAGR* until 2022 of 4%, 10% and 18%, respectively

4. Strong FCF along with proceeds from divestments enable (i) growing dividends, (ii) quick deleveraging of our balance sheet and (iii) selective bolt-ons and in-licensing transactions

2018e PF used for Sales and Core EPS; 2018e used for FCF
We Will Make Further Portfolio Adjustments: Crystallizing Value of Non-core Assets

<table>
<thead>
<tr>
<th>Portfolio assets</th>
<th>Rationale</th>
<th>Financials (2018e)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Animal Health</strong></td>
<td>// Explore strategic exit options for <strong>Animal Health</strong></td>
<td>~€1.5bn ~€0.35bn</td>
</tr>
<tr>
<td></td>
<td>// Inorganic investments required to build a leading position will be shifted to other investment priorities</td>
<td></td>
</tr>
<tr>
<td><strong>CURRENTA</strong></td>
<td>// Explore strategic options for share in <strong>CURRENTA</strong></td>
<td>~€1.2bn ~€0.2bn</td>
</tr>
<tr>
<td></td>
<td>// Non-core business; mismatch between Bayer’s ownership share (60%) and demand of services (20%)</td>
<td></td>
</tr>
<tr>
<td><strong>Coppertone</strong></td>
<td>// Explore strategic options for <strong>Suncare &amp; Footcare</strong></td>
<td>~€0.4bn N/A</td>
</tr>
<tr>
<td></td>
<td>// Crystallize value of consumer care brands to focus capital allocation on core OTC brands</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>~€3.1bn &gt;€0.6bn</td>
</tr>
</tbody>
</table>

Total: ~€3.1bn >€0.6bn
Transformation Completed

**Group Profile**

- HealthCare, Consumer Care, Diagnostics, Animal Health

**Today:**
- Crop Science: Polyurethanes, Coatings, Fibres
- Pharma-ceuticals, Biological Products
- Polymers: Plastics, Rubber
- Consumer Health
- Crop Science
- Pharma-ceuticals
- Consumer Health

**Measures**

- Organic top-line growth and profitability improvement
- Transformational M&A in all of today’s businesses
- Synergies realized from strategic acquisitions
- Value crystallized through optimally-timed divestments
- Shaping the future of Health & Nutrition
- Adjusted set-up for future value creation
We are a Global Leader in Health & Nutrition
Well-Positioned Across Our Businesses

~€45bn 2018 Pro-forma Sales\(^1\)

<table>
<thead>
<tr>
<th>Crop Science</th>
<th>Pharmaceuticals</th>
<th>Consumer Health</th>
</tr>
</thead>
<tbody>
<tr>
<td>~€19bn / ~43% of Group</td>
<td>~€17bn / ~38% of Group</td>
<td>~€5bn / ~12% of Group</td>
</tr>
<tr>
<td>#1 Position</td>
<td>#2 Position in Cardiovascular</td>
<td>#2 Position</td>
</tr>
</tbody>
</table>

Growing ahead of competition over last five years on average
Best-in-class profitability through the cycle
// Leading portfolio of seed & traits, crop protection and digital farming
// World-class R&D platform with best talent and technology in the industry
// Positioned to shape the future of agriculture: development of tailored solutions to address farmers’ individual needs and challenges

One of the fastest growing Pharma businesses over the past five years
Xarelto and Eylea among the world’s leading Pharma brands
// Innovative medicines in areas of high unmet medical need
// Therapeutic focus areas: Cardiology, Oncology, Gynecology, Hematology and Ophthalmology
// Strong position in emerging markets
// Leading in Radiology and Women’s Health

Leading Positions in 7 of the Top 10 OTC Markets
// Focus categories: Allergy & Cold, Cough, Sinus and Flu; Nutritionals; Dermatology; Pain and Cardio; Digestive Health
// Concentrated portfolio of 16 mega-brands with annual sales of >€100m

\(^1\) The unaudited Pro-forma data are presented as if both the acquisition of Monsanto and the associated divestments had taken place as of January 1, 2018. Sales of Monsanto are presented in periods as per the Bayer fiscal year. One-time effects of business operations, the accounting for discontinued operations and the recognition and measurement of sales from certain business transactions have been adjusted in line with our accounting. Due to this simplified procedure, they explicitly do not reflect sales according to IFRS or IDW RH HFA 1.004, meaning they have not been audited.
Next Phase to Deliver Value Creation

<table>
<thead>
<tr>
<th>Transformation Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crop Science</td>
</tr>
<tr>
<td>Pharmaceuticals</td>
</tr>
<tr>
<td>Consumer Health</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Next Phase Focused on …</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Growth ahead of competition in Health and Nutrition</td>
</tr>
<tr>
<td>2. Consistent profitability enhancement</td>
</tr>
<tr>
<td>3. Strong free cash flow generation</td>
</tr>
<tr>
<td>4. Disciplined capital allocation</td>
</tr>
</tbody>
</table>
Global Megatrends in Health & Nutrition

Attractive Macro Drivers of Our Businesses

Megatrends through 2050

Societal Needs

Our Mission

Aging Population

Growing Population

Pressure on Ecosystems

People 60+ more than doubling

+2.2bn people

+50%

>20% of total population

more food and feed required to meet growing demand

Preserve and restore health

Secure sufficient supply of quality food

Use natural resources more efficiently and responsibly

Harvest losses from climate change

-17%

-20%

2016 2050

Significant loss in arable land per capita

We leverage science to address these societal needs – with the ultimate goal to improve people’s lives

2 FAO 2017, (FAO Global Perspective Studies)
3 Nelson et. al, (2014); FAO 2016 “Climate change and food security”
We Focus on Growth in Attractive Markets

### Bayer Group

<table>
<thead>
<tr>
<th>Market</th>
<th>Size 2017</th>
<th>CAGR 2018-2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crop Science</td>
<td>~€90bn(^1)</td>
<td>~3% (^2)</td>
</tr>
<tr>
<td>Pharmaceuticals</td>
<td>~€870bn(^3)</td>
<td>4-5%</td>
</tr>
<tr>
<td>Consumer Health</td>
<td>~€140bn(^4)</td>
<td>3-4%</td>
</tr>
</tbody>
</table>

### Bayer’s growth levers

- Using our leading positions in Agriculture, Pharmaceuticals and Self-care to address societal needs and benefit from global megatrends
- Drive innovation
- Leading portfolio of seed & traits, crop protection and digital farming
- World-class R&D platform with best talent and technology in the industry
- Positioned to shape the future of agriculture: Development of tailored solutions to address farmers’ individual needs and challenges
- Innovative medicines in areas of high unmet medical need
- Therapeutic focus areas: Cardiology, Oncology, Gynecology, Hematology and Ophthalmology
- Leverage external innovation and partnering as well as pipeline and potential of current products
- Branded self-care solutions that help transform people’s daily health
- Focus on five core categories

---

\(^1\) Pro-forma calculations Bayer, Bayer CS market model; \(^2\) excluding potential cyclical recovery of the Crop Science market; \(^3\) IQVIA; \(^4\) Market model in-market sales OTC medicines, data from IQVIA, Nicholas Hall
## Bayer 2022 Synergy & Efficiency Programs

<table>
<thead>
<tr>
<th>Platform</th>
<th>Crop Science</th>
<th>Consumer Health</th>
<th>Pharmaceuticals</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Realization of Crop Science sales and cost synergies</td>
<td>Comprehensive growth acceleration program</td>
<td>Re-alignment of R&amp;D activities towards external innovation / Hemophilia production footprint</td>
</tr>
<tr>
<td></td>
<td>~€0.17bn (=$0.2bn) sales synergies¹</td>
<td>~€0.4bn contribution</td>
<td>~€0.2bn contribution</td>
</tr>
<tr>
<td></td>
<td>~€0.47bn (=$0.55bn) cost synergies</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>~€0.40bn (=$0.45bn) cost synergies</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adjustment of corporate platform</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>~€0.9bn contribution</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

¹ EBITDA before special items impact from sales synergies
² Indicative Phasing: ~30% effective in 2020, ~70% in 2021 and 100% in 2022

### Overall Contribution
~€2.6bn²

### Global FTE impact
~12,000

### One-Time Cost
~1.7X
### Targeting Significant Profitability Improvements Across All Divisions

Sales and EBITDA before special items (margin) development (in €bn, %)

<table>
<thead>
<tr>
<th>Division</th>
<th>2018e PF</th>
<th>2019 Indicative Guidance</th>
<th>Target 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Crop Science</strong></td>
<td>19.3</td>
<td>~23%</td>
<td>&gt;30%</td>
</tr>
<tr>
<td><strong>Pharmaceuticals</strong></td>
<td>16.8</td>
<td>~33%</td>
<td>&gt;35%</td>
</tr>
<tr>
<td><strong>Consumer Health</strong></td>
<td>5.5</td>
<td>~20%</td>
<td>&gt;30%</td>
</tr>
<tr>
<td><strong>Bayer Group</strong></td>
<td>44.6</td>
<td>~26%</td>
<td>&gt;30%</td>
</tr>
</tbody>
</table>

- **Indicative Guidance**
  - Crop Science: ~4% margin development, ~4% p.a.
  - Pharmaceuticals: ~4% margin development, ~4-5% p.a.
  - Consumer Health: ~1% margin development, ~2% p.a.
  - Bayer Group: ~4% margin development, ~4-5% p.a.

- **2022 Targets** (at constant currencies, not including portfolio measures (except for Consumer Health))
  - Crop Science: 19.3 €bn, ~23% margin
  - Pharmaceuticals: 16.8 €bn, ~33% margin
  - Consumer Health: 5.5 €bn, ~20% margin
  - Bayer Group: 44.6 €bn, ~26% margin

1 Includes portfolio measures

---

2022 targets at constant currencies, not including portfolio measures (except for Consumer Health)
Cash Flow Improvement Focusing on Capex and Working Capital Optimization

**Capex spend in €bn**

- **2016**: 9.3
- **2010**: 10.1
- **2012**: 12.0
- **2014**: 9.5
- **2016**: 9.9
- **2018e**: 15.0

**in % of sales**

- **2010**: 4.3%
- **2012**: 4.9%
- **2014**: 5.7%
- **2016**: 7.4%
- **2017**: 6.0%
- **2018e**: 7.0%

**Focused CapEx below current levels ~ 5-6%**

- **Crop Science**: 48%
- **Pharmaceuticals**: 24%
- **Consumer Health**: 24%

**Working Capital in €bn**

- **2010**: 9.3
- **2012**: 10.1
- **2014**: 12.0
- **2016**: 9.5
- **2017**: 9.9
- **2018e**: 15.0

**in % of sales**

- **2010**: 26%
- **2012**: 25%
- **2014**: 29%
- **2016**: 27%
- **2017**: 28%
- **2018e**: 34%

**Working capital optimization ~ 32%**

- **Annual contribution of ~0.5bn EUR by 2022**
- **Past and current levels impacted by single large-scale investments in fixed assets**
- **Licensing will continue to be an element to drive growth**

- **Annual contribution of ~0.5bn EUR by 2022**
- **Focus on optimization of inventory levels and receivables management**

---

1 Crop Science 48%, Pharmaceuticals 24%, Consumer Health 24%; 2 Working Capital estimated at year-end
## Group Targets - Value Creation from Strengthened Base

### Triple Leverage

<table>
<thead>
<tr>
<th>€bn</th>
<th>2018e PF</th>
<th>Indicative Guidance 2019</th>
<th>Target 2022</th>
<th>CAGR 2018-22²</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sales¹</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Group</td>
<td>44.6</td>
<td>~46 (~4%)</td>
<td>~52</td>
<td>~4%</td>
</tr>
<tr>
<td>Crop Science</td>
<td>19.3</td>
<td>~4%</td>
<td></td>
<td>&gt;4%</td>
</tr>
<tr>
<td>Pharmaceuticals</td>
<td>16.8</td>
<td>~4%</td>
<td></td>
<td>~4-5%</td>
</tr>
<tr>
<td>Consumer Health</td>
<td>5.5</td>
<td>~1%</td>
<td></td>
<td>~2%</td>
</tr>
<tr>
<td><strong>EBITDA before special items (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Group</td>
<td>11.5 (~26%)</td>
<td>~12.2 (~27%)</td>
<td>~16 (&gt;30%)</td>
<td>~9%</td>
</tr>
<tr>
<td>Crop Science</td>
<td>4.5 (~23%)</td>
<td>~25%</td>
<td>&gt;30%</td>
<td></td>
</tr>
<tr>
<td>Pharmaceuticals</td>
<td>5.6 (~33%)</td>
<td>~34%</td>
<td>&gt;35%</td>
<td></td>
</tr>
<tr>
<td>Consumer Health</td>
<td>1.1 (~20%)</td>
<td>~21%</td>
<td>~24%⁴</td>
<td></td>
</tr>
<tr>
<td><strong>Core EPS (€)</strong></td>
<td></td>
<td></td>
<td></td>
<td>~10%</td>
</tr>
<tr>
<td>~6.7</td>
<td>~6.8</td>
<td>~10</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>FCF</strong></td>
<td></td>
<td></td>
<td></td>
<td>~18%</td>
</tr>
<tr>
<td>~4.1³</td>
<td>~3-4</td>
<td>~8</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Net financial debt</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>~36³</td>
<td>~36⁵</td>
<td>~26-28</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

¹ Sales: cpa growth; ² CAGR from 2018 base year; ³ FCF 2018e (as reported); ⁴ includes portfolio measures; ⁵ including around ~€1bn lease liability due to IFRS 16
We Have Clear Priorities for Capital Allocation

Focus on Shareholder Return, Innovation and Deleveraging

Disciplined capital allocation

- Shareholder Return
  - Growing dividends
  - Consider share buy backs with parts of divestment proceeds

- Deleveraging
  - Target range ~€26-28bn\(^1\) net financial debt by end 2022

- Innovation & Acquisitions
  - Investment in licensing opportunities
  - Potentially selective bolt-on acquisitions

\(^1\) Before M&A / Portfolio

Divestment proceeds

Free Cash Flow Targeted

~€23bn
2019e-2022e

Animal Health
We Will Create Significant Value Through 2022 and Beyond
Focus on Execution and Driving Sustained Profitable Growth…

1. We have completed Bayer’s portfolio transformation into a global leader in Health & Nutrition

2. The next phase is focused on driving value creation through (i) growth ahead of competition enabled by innovation and portfolio measures (ii) profitability enhancement through Bayer 2022 synergy and efficiency programs and (iii) strong cash generation

3. We target Sales, Core EPS and FCF CAGR* until 2022 of 4%, 10% and 18%, respectively

4. Strong FCF along with proceeds from divestments enable (i) growing dividends, (ii) quick deleveraging of our balance sheet and (iii) selective bolt-ons and in-licensing transactions

2018e PF used for Sales and Core EPS; 2018e used for FCF
Pharma
Innovative Medicines in Areas of High Unmet Medical Need

**Therapeutic area focus**
- Cardiovascular
- Hematology
- Oncology
- Ophthalmology
- Radiology
- Women’s Health
- Other

**Emerging markets exposure**
- Sales 2017: €16.8bn
- Established Markets: 68%
- Emerging Markets: 32%

**Global leadership in important therapeutic areas**
- No. 1 in Retinal Diseases
- No. 1 in Women’s Health
- No. 1 in Radiology
- No. 2 in Cardiovascular
- No. 2 in Hematology

**Leading Brands**

Emerging markets include Latin America, Asia (w/o Japan, Australia, New Zealand), Africa and Middle East incl. Turkey, Eastern Europe
Pharma

Xarelto – Continued Growth of a Leading Anticoagulant

Sales in €bn

<table>
<thead>
<tr>
<th>Year</th>
<th>Sales in €bn</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>0.9</td>
</tr>
<tr>
<td>2014</td>
<td>1.7</td>
</tr>
<tr>
<td>2015</td>
<td>2.3</td>
</tr>
<tr>
<td>2016</td>
<td>2.9</td>
</tr>
<tr>
<td>2017</td>
<td>3.3</td>
</tr>
</tbody>
</table>

// Most broadly indicated anticoagulant for use in venous and arterial thromboembolic conditions

// A leading pharma brand with global sales of €5.0bn in 2017 incl. sales at Johnson & Johnson

// New CAD/PAD indication launching in EU and the US

// Peak sales potential: >€5.0bn

// Further growth driven by:
  // Under-served patient populations
  // Demographics
  // Shift from warfarin
  // New indications targeting patients currently not treated with anticoagulants

CAD: Coronary artery disease; PAD: Peripheral artery disease

Ex-US sales plus royalty from J&J as reported by Bayer
A leader in retinal diseases with global brand sales of €5.2bn in 2017 incl. sales at Regeneron

Approved for the treatment of 5 retinal diseases: wAMD, DME, BRVO, CRVO, mCNV

Treat and extend dosing regimen with injection intervals of up to 12 weeks or more for wAMD

Peak sales potential: >€2.5bn

Further growth driven by:
- Continued generation of real-life experience in wAMD across key markets and treatment-naïve patient share gains
- Market expansion in DME

1 Marketed by Bayer ex-US only; 2 As reported by Bayer

wAMD: Wet age related macular degeneration; DME: Diabetic macular edema; BRVO: Branch retinal vein occlusion; CRVO: Central retinal vein occlusion; mCNV: Myopic choroidal neovascularization
Pharma

China is a Growth Engine for Pharma

Sales in PR China in €bn

- 2013: 1.3
- 2015: 1.8
- 2017: 2.0
- 2022 target: ~3.0

~13% CAGR cpa

// Ranked among the top 5 multi-national pharma companies in China

// Targeting sales of ~€3bn in PR China by 2022

// Portfolio of established and innovative drugs matches China’s needs

// Strong growth of key products

// Xarelto and Nexavar entered the National Reimbursement Drug List in 2017

// Glucobay, Adalat, Nimotop, Bayaspirin and Ciprobay listed on China’s Essential Drug List

cpa: Currency and portfolio adjusted
Pharma
Late-stage Pipeline with Progress in Oncology
Darolutamide met Primary Endpoint in Phase III-trial and FDA-approval of Larotrectinib

<table>
<thead>
<tr>
<th>Indication</th>
<th>Status</th>
<th>Commercial Potential</th>
<th>Clinical Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Larotrectinib</td>
<td>TRK-fusion Cancer</td>
<td>PSP &gt;€750m</td>
<td>Clinical program ongoing</td>
</tr>
<tr>
<td></td>
<td>FDA approved / in registration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Darolutamide</td>
<td>Prostate Cancer</td>
<td>PSP &gt;€1bn</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Phase III (nmCRPC)</td>
<td>PSP &gt;€0.5bn</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Completed (ARAMIS, nmCRPC)</td>
<td>May 2020e</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aug 2022e (ARASENS, mHSPC)</td>
<td>Sep 2021e</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Copanlisib</td>
<td>Lymphoma</td>
<td>PSP &gt;€1bn</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Launched in the US</td>
<td>PSP &gt;€0.5bn</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Phase III</td>
<td>May 2020e</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(CHRONOS-3)</td>
<td>Sep 2021e</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(CHRONOS-4)</td>
<td>Jul 2021e</td>
<td></td>
</tr>
<tr>
<td>Finerenone</td>
<td>Diabetic Kidney Disease</td>
<td>PSP &gt;€1bn</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Phase III</td>
<td>May 2020e</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(FIDELIO-DKD)</td>
<td>Jul 2021e</td>
<td></td>
</tr>
<tr>
<td>Vericiguat</td>
<td>Chronic Heart Failure</td>
<td>PSP ~€0.5bn</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Phase III (HFrEF)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Phase II (HFpEF)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PSP ~€0.5bn</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jan 2020e (VICTORIA, HFrEF)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oct 2019e (VITALY, HFpEF)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NTRK: Neurotrophic receptor tyrosine kinase; nmCRPC: Non-metastatic castration resistant prostate cancer; mHSPC: Metastatic hormone sensitive prostate cancer; HFrEF: Heart failure with reduced ejection fraction; HFpEF: Heart failure with preserved ejection fraction; PSP: Peak sales potential
## Consumer Health
### Strong Consumer Brands Built up Over Decades

<table>
<thead>
<tr>
<th>Brand</th>
<th>Category</th>
<th>Age</th>
<th>Sales 2017</th>
<th>CAGR 2013-2017</th>
<th># of studies</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASPIRIN</strong></td>
<td>Pain, Cardio, Cough &amp; Cold</td>
<td>119</td>
<td>€1,043m³</td>
<td>2.6%</td>
<td>88</td>
</tr>
<tr>
<td><strong>Claritin</strong></td>
<td>Allergy</td>
<td>25¹</td>
<td>€585m</td>
<td>2.2%</td>
<td>82</td>
</tr>
<tr>
<td><strong>Bepanthen</strong></td>
<td>Dermatology</td>
<td>74</td>
<td>€379m</td>
<td>9.7%</td>
<td>116</td>
</tr>
<tr>
<td><strong>ALEVE</strong></td>
<td>Pain</td>
<td>42¹</td>
<td>€375m</td>
<td>1.3%</td>
<td>42</td>
</tr>
<tr>
<td><strong>Alka-Seltzer</strong></td>
<td>Digestive Health, Cough &amp; Cold</td>
<td>87</td>
<td>€244m</td>
<td>4.4%</td>
<td>7</td>
</tr>
<tr>
<td><strong>elevit</strong></td>
<td>Nutritionals</td>
<td>34</td>
<td>€189m</td>
<td>17.1%</td>
<td>6</td>
</tr>
</tbody>
</table>

¹ Rx launch; ² Past 20 years of clinical data; ³ Combined sales (Consumer Health and Pharmaceuticals)
Consumer Health
We Will Focus on our Core OTC Categories To Leverage our Science and Marketing Capabilities

**Categories to accelerate**

- Allergy + Cough + Cold #5
- Nutritionals #2
- Dermatology #2
- Pain + Cardio #4
- Digestive Health #2

**Categories to exit**

- Divestment of Rx Dermatology - US business closed; closing ex-US expected in H2 2019
- Explore exit options for Sun- and Footcare in 2019

---

1 Excluding Derma Rx, Suncare, Footcare
2 PARS database December 2017
3 Subject to the fulfillment of customary closing conditions
Levers and key focus areas

**People & Organization**
- Increase category and brand building experience
- Drive leaner more agile organization

**Winning Portfolio**
- Focus our resources on categories where we can win
- Rebuild innovation pipeline

**Accelerate growth-focused Innovation**
- Rebuild brand fundamentals
- Accelerate digital

**Modernized Marketing & Sales**
- Rebuild brand fundamentals
- Accelerate digital

First actions

**People & Organization**
- Right-size the organization
- New leadership team in place

**Winning Portfolio**
- Divested Rx Dermatology
- Explore exit options: Suncare / Footcare

**Accelerate growth-focused Innovation**
- Strengthen innovation for core brands
- Establish Rx-to-OTC switch pipeline

**Modernized Marketing & Sales**
- Step up e-commerce
  - Amazon 2018e sales +60%
  - Online (8.3%) to offline (8.7%) share

Q4 2018
Q1 2019
H2 2018
2019
2020
2018
Consumer Health
Our Strategic and Operational Roadmap

2018
- Setting the foundation
  - Strategic focus
    - Put in new leadership team
    - Make portfolio choices
    - Initiate stricter cost control
    - Make necessary impairments
  - Growth
    - Stabilize growth
  - Profitability
    - Stop margin erosion through strict cost controls

2019 / 2020
- Driving rigorous change
  - Strategic focus
    - Execute portfolio choices
    - Right-size cost base
    - Recover product supply
    - Regain momentum in APAC/EMEA
    - Reset US cost base to strengthen margin
  - Growth
    - Return to growth
  - Profitability
    - Improve margins

2021 / 2022
- Acceleration phase
  - Strategic focus
    - Drive higher innovation level
    - Accelerate US growth momentum
    - Capitalize on portfolio choices
    - Realize full benefit of efficiency program
  - Growth
    - Accelerate growth
  - Profitability
    - Accelerate margins
Crop Science
The Established Leader in Crop Science
Grower Endorsement of Excellent Product Portfolio Evidenced by Industry Leading Sales

BroDEST Crop Science Product Portfolio

Sales 2017 (€bn)

<table>
<thead>
<tr>
<th></th>
<th>Bayer Crop Science¹</th>
<th>ChemChina Ag²</th>
<th>Corteva</th>
<th>BASF Ag³</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seeds &amp; Traits</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crop Protection</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pro-forma acquired divestments</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

20.1
14.1
12.7
7.9

¹ The unaudited Pro-forma data are presented as if both the acquisition of Monsanto and the associated divestments had taken place as of January 1, 2017. Sales of Monsanto are presented in periods as per the Bayer fiscal year. One-time effects of business operations, the accounting for discontinued operations and the recognition and measurement of sales from certain business transactions have been adjusted in line with our accounting.
² Excludes non-agro business sales of ADAMA (nutritional supplements, aromatic products, industrial products)
³ Includes BASF Ag Sales 2017 as reported (€ 5.7bn) plus €2.2bn Pro-forma sales in 2017 from Bayer businesses sold to BASF
Crop Science
Leading Position in All Major Categories

Crop Science Market currently valued at ~€90bn // ~3% Long-term CAGR Expected

Corn
- ~€20bn market
  - #1 position

Soybean
- ~€15bn market
  - #1 position

Horticulture
- ~€15bn market
  - #1 position

Cereals
- ~€10bn market
  - #1 position

Digital Farming
- Climate FieldView Digital Platform
  - #1 position

Note: Reflecting BCS’ portfolio after divestments. Market sizes rounded to nearest $5bn. Source: Pro-forma calculations Bayer; Bayer CS market model.

1 Includes fruits, vegetables, flowers and nuts
2 Includes seeds, traits, crop protection chemistries and environmental science; does not include fertilizer
Crop Science
World’s Broadest Commercial Footprint in Agriculture

~7,800 Customer-facing Employees with Significant Opportunity to Optimize Portfolio Across Key Regions

Sales 2017¹: €20.1bn

Seed & Trait Technology Acres 2017/2018²:
>400m acres (160m ha)

Crop Protection Sales 2017¹: ~€9.5bn

¹ The unaudited Pro-forma data are presented as if both the acquisition of Monsanto and the associated divestments had taken place as of January 1, 2017. Sales of Monsanto are presented in periods as per the Bayer fiscal year. One-time effects of business operations, the accounting for discontinued operations and the recognition and measurement of sales from certain business transactions have been adjusted in line with our accounting. Rounded to the nearest 5%.

² Internal estimates; represents acres containing at least one Bayer seed or biotech trait technologies.
Crop Science
Unmatched Investment in R&D
Shaping the Future of Agriculture with Most Productive Innovation Platform in the Industry

#1 R&D Platform in Crop Science

// ~7,300 R&D employees

// >35 R&D sites

// >175 breeding locations delivering innovation

// Partner of choice

// Technology provider to the industry

2017 Ag R&D Investment (€bn)¹

<table>
<thead>
<tr>
<th>Company</th>
<th>Seed &amp; Traits</th>
<th>Crop Protection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bayer Crop Science</td>
<td>2.4</td>
<td></td>
</tr>
<tr>
<td>Corteva</td>
<td>1.4</td>
<td></td>
</tr>
<tr>
<td>ChemChina Ag</td>
<td>1.2</td>
<td></td>
</tr>
<tr>
<td>BASF Ag</td>
<td>0.6</td>
<td></td>
</tr>
</tbody>
</table>

¹ Pro-forma estimates based on company information and internal calculations. Bayer Pro-forma figures consider Monsanto acquisition and related divestments. Monsanto calendarized to twelve-month-period ended November 30, 2017.
Crop Science
Next Growth Opportunity: Convergence of Leading R&D Platforms

Extensive Germplasm and Biotech Foundation, Combined with Leadership in Chemistry and Biologicals and Data Science Optimization, Serves As Innovation Engine To Accelerate Benefits Across The Industry

- Leading germplasm libraries in corn, soybean, cotton and vegetables
- Reach >350m acres annually
- >20 new and next-generation traits in development
- #1 field trial footprint

Strong discovery platform for molecules with new mode-of-action and differentiated profiles
- 30-60 molecules selected for field trials annually
- Leader in formulation technology

>10,000 microbes screened in vitro annually

>80m acres of commercial products reached annually in row crops

60m paid acres in U.S.A., Brazil and Europe represents industry’s leading platform reach

#1 database of grower and field trial seed performance data in the industry

Extensive Germplasm and Biotech Foundation, Combined with Leadership in Chemistry and Biologicals and Data Science Optimization, Serves As Innovation Engine To Accelerate Benefits Across The Industry

Best positioned to discover, combine and tailor solutions for growers
Crop Science
Driving the Largest and Most Valuable R&D Pipeline in Ag
Highly Effective in Converting Investment into Meaningful Products for Farmers

Newly Combined Pipeline

<table>
<thead>
<tr>
<th>Scale</th>
<th>Advancements</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Unmatched in the Industry</strong></td>
<td><strong>Outpacing Competitors</strong></td>
<td><strong>Up to €30bn Peak Sales(^1)</strong></td>
</tr>
<tr>
<td>// &gt;75 projects in seed &amp; traits, crop protection and digital ag pipelines</td>
<td>// &gt;70 advancements in 2016 and 2017</td>
<td>// Potential to accelerate with combined pipelines</td>
</tr>
<tr>
<td>// 100’s of new hybrids and varieties commercialized annually</td>
<td>// &gt;50 advancements in 2018</td>
<td>// Climate tools serve as an enabler to reach peak opportunity</td>
</tr>
</tbody>
</table>

Peak Sales Opportunity by Crop

- **Corn**: ~ €11-14bn
- **Soybean**: ~ €6-7bn
- **Cereals & Other**: ~ €4-5bn
- **Horticulture**: ~ €3-4bn

\(^1\) Represents non-risk adjusted estimated peak sales for the combined breeding, biotech, crop protection and environmental science pipelines. Applied FX rate of USD/EUR of 1.15
Our Value Creation is Supported by our Performance Trends; Paid Acres >7x Closest Competitor

**Global Paid Acres\(^1\)**

<table>
<thead>
<tr>
<th>Year</th>
<th>Paid Acres</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY15</td>
<td>5m</td>
</tr>
<tr>
<td>FY16</td>
<td>15m</td>
</tr>
<tr>
<td>FY17</td>
<td>&gt;35m</td>
</tr>
<tr>
<td>FY18e</td>
<td>60m</td>
</tr>
<tr>
<td>FY19 Target</td>
<td>90m</td>
</tr>
</tbody>
</table>

**#1 platform in the digital Ag space**

**#1 brand in the digital Ag space**

**Brand Health\(^2\) (U.S.)**

- **Awareness**
  - 77%

- **Familiarity**
  - 65%

- **Consideration**
  - 44%

- **Have Used**
  - 37%

- **Currently Use**
  - 33%

- **FarmLogs\(^\text{TM}\)**, **John Deere\(^\text{TM}\)**, **FarmersEdge\(^\text{TM}\)**

---

1 Internal estimates
2 2018 Brand Health Monitor

**>35 next-generation projects in the pipeline**